Testosterone in ageing men

Expert Opinion on Investigational Drugs

Volumn 10, Issue 3, 2001, Pages 477-492

  Gambineri, A ^a   Pelusi, C ^a   Vicennati, V ^a   Pagotto, U ^a   Pasquali, R ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Ageing; Delivery system; Hypogonadism; Male; Testosterone

Indexed keywords

ANDROGEN; CASTOR OIL; CYCLODEXTRIN DERIVATIVE; FLUOXYMESTERONE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYPROLINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MICROSPHERE; MUSCLE PROTEIN; PLACEBO; TESTOSTERONE; TESTOSTERONE 4 BUTYLCYCLOHEXANECARBOXYLATE; TESTOSTERONE CIPIONATE; TESTOSTERONE ENANTATE; TESTOSTERONE PROPIONATE; TESTOSTERONE UNDECANOATE; VEGETABLE OIL;

AGING; ANIMAL EXPERIMENT; ANIMAL MODEL; BODY FAT; BONE DENSITY; BONE MINERAL; CHEMICAL MODIFICATION; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG FORMULATION; DRUG STRUCTURE; DRUG TOLERABILITY; GRIP STRENGTH; HORMONAL THERAPY; HORMONE SUBSTITUTION; HUMAN; HYPOGONADISM; IMPLANTATION; LIBIDO; LONG TERM CARE; MALE; MUSCLE STRENGTH; NONHUMAN; POLYCYTHEMIA; RAT; REVIEW; SCROTUM; SLOW RELEASE FORMULATION; TABLET; TRANSDERMAL PATCH;

AGED; AGING; HORMONE REPLACEMENT THERAPY; HUMANS; MALE; TESTOSTERONE;

EID: 0035117426     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.10.3.477     Document Type: Review

References (89)

1. Age, disease and changing sex hormone levels in middle-aged men: Results of the Massachusetts male aging study
2. Changes in serum concentrations of conjugated and unconjugated steroids in 40- to 80-year-old men
3. The aging male reproductive system
4. Testosterone therapy in men: Clinical and pharmacological perspectives
5. Androgens in the aging male
6. Loss of circadian rhythmicity in blood testosterone levels with aging in normal men
7. Attenuation of luteinizing hormone secretory burst amplitude as a proximate basis for the hypoandrogenism of healthy aging men
8. The gonadotropic suppressive activity of androgens is increased in elderly men
9. Serum LH concentrations in hypogonadal men during transdermal testosterone replacement through scrotal skin: Further evidence that aging enhances testosterone negative feedback
10. Influence of some biological indices on sex hormone binding globulin and androgen levels in aging and obese males
11. Testosterone and frailty
12. Testosterone replacement and the physiologic aspects of aging in men
13. Issues in testosterone replacement in older men
14. Androgens in male senescence
15. Canadian practice recommendations for screening, monitoring and treating men affected by andropause or partial androgen deficiency
16. Pharmacology and clinical uses of testosterone
17. Lymphatic absorption and metabolism of orally administered testosterone undecanoate in men
18. The pharmacology and metabolism of testosterone undecanoate (TU), a new orally active androgen
19. Plasma androgen levels in men after oral administration of testosterone or testosterone undecanoate
20. Saliva and serum testosterone following oral testosterone undecanoate administration in normal and hypogonadal men
21. The influence of the amount of solvent (sesame oil) on the degree and duration of action of subcutaneously administered testosterone and its propioate
22. 14C testosterone and some of its esters after injection into the rat
23. Emerging issues in androgen replacement therapy
24. Pharmacokinetic properties of testosterone propionate in normal men
25. Model studies in vitro with long-acting hormonal preparations
26. Bioavailability and LH-suppressing effect of different testosterone preparations in normal and hypogonadal men
27. Comparison of testosterone, dihydrotestosterone, luteinizing hormone and follicle-stimulating hormone in serum after injection of testosterone enanthate or testosterone cypionate
28. Hormone kinetics after intramuscular testosterone cypionate
29. Treatment of male hypogonadism with testosterone enanthate
30. Comparison of the kinetics of injectable testosterone in eugonadal and hypogonadal men
31. Comparative pharmacokinetics of testosterone esters
32. Hypogonadal men treated with the Androderm testosterone transdermal system had fewer abnormal hematocrit elevations than those treated with testosterone enanthate injections
33. A permeation-enhanced non-scrotal testosterone transdermal system for the treatment of male hypogonadism
34. Pharmacokinetics and pharmacodynamics of testosterone pellets in man
35. Clinical pharmacology of testosterone pellet implants
36. 14C cortisol in man
37. Testosterone replacement with transdermal therapeutic systems
38. Transdermal delivery of testosterone
39. Androgen therapy of hypogonadal men with transscrotal testosterone systems
40. Transdermal testosterone therapy in the treatment of male hypogonadism
41. Treatment of primary hypogonadism in men by the transdermal administration of testosterone
42. The conversion of testosterone to 5 α-androstane-1β7-ol-3 one (dihydrotestosterone) by skin slices of men
43. Transdermal testosterone replacement through genital skin
44. Pharmacokinetics and metabolism of a permeation-enhanced testosterone transdermal system in hypogonadal men: Influence of application site-a clinical research center study
45. Enhanced transdermal delivery of testosterone across non scrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men
46. Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men
47. Bioequivalence assessment of a single 5 mg/day testosterone transdermal system versus two 2.5 mg/day systems in hypogonadal men
48. Adverse dermatologic reactions to transdermal drug delivery systems
49. Pre-treatment with a topical corticosteroid cream improves local tolerability and does not significantly alter the pharmacokinetics of the androderm testosterone transdermal system in hypogonadal men
50. Use of topical corticosteroid cream in the pretreatment of skin reactions associated with Androderm testosterone transdermal system
51. Trandermal testosterone administration in hypogonadal men: Comparison of pharmacokinetics at different sites of application and at the first and fifth days of application
52. Testosterone pharmacokinetics after application of an investigational transdermal system in hypogonadal men
53. Comparison of the skin irritation potential of two testosterone transdermal systems: An investigational system and a marketed product
54. Pharmacokinetics of transdermal testosterone gel in hypogonadal men: Application of gel at one site versus four sites: A general clinical research center study
55. Transdermal testosterone gel improves sexual function, mood, muscle strength and body composition parameters in hypogonadal men
56. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men
57. Sublingual administration of testosterone-hydroxypropyl-β-cyclodextrin inclusion complex simulates episodic androgen release in hypogonadal men
58. Pharmacokinetics, bioefficacy and safety of sublingual testosterone cyclodextrin in hypogonadal men: Comparison to testosterone enanthate - A clinical research center study
59. Sublingual testosterone replacement improves muscle mass and strength, decreases bone resorption and increases bone formation markers in hypogonadal men - A clinical research center study
60. Pharmacokinetic characteristics, efficacy and safety of buccal testosterone in hypogonadal males: A pilot study
61. Initial trial of slow-release testosterone microspheres in hypogonadal men
62. A biodegradable testosterone microcapsule formulation provides uniform eugonadal levels of testosterone for 10-11 weeks in hypogonadal men
63. Pharmacokinetics and pharmacodynamics of a parenteral testosterone microsphere formulation in the male rat. Demonstration of dose dependence and controlled release
64. New injectable testosterone ester maintains serum testosterone of castrated monkeys in the normal range for four months
65. Testosterone buciclate (20 Aet-1) in hypogonodal men: Pharmacokinetics and pharmacodynamics of the new long-acting androgen ester
66. Injectable testosterone undecanoate has more favourable pharmacokinetics and pharmacodynamics than testosterone enanthate
67. Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: Phase I studies
68. Repeated intramuscular injections of testosterone undecanoate for substitution therapy in hypogonadal men
69. A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men
70. Large porous particles for pulmonary drug delivery
71. Effects of testosterone supplementation in the aging male
72. Effects of testosterone replacement therapy in old hypogonadal males: A preliminary study
73. Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis
74. Androgen treatment of abdominally obese men
75. Testosterone replacement in older hypogonadal men: A 12-month randomized controlled trial
76. Effect of testosterone treatment on bone mineral density in men over 65 years of age
77. Identification of androgen receptors in normal human osteoblast-like cells
78. Androgens directly stimulate proliferation of bone cells in vitro
79. Androgen and progestagen effects on plasma lipids
80. Effect of testosterone replacement therapy on lipids and lipoproteins in hypogonadal and elderly men
81. Dihydrotestosterone and testosterone levels in men screened for prostate cancer: A study of a randomized population
82. Longitudinal evaluation of serum androgen levels in men with and without prostate cancer
83. A prospective study of plasma hormone levels, non hormonal factors and development of benign prostatic hyperplasia
84. Outcomes of long-term testosterone replacement in older hypogonadal males: A retrospective analysis
85. Androgens and erythropoiesis
86. Biological actions of androgens
87. Bioavailable testosterone and depressed mood in older men: The Rancho Bernardo study
88. Testosterone supplementation for hypogonadal impotence: Assessment of biochemical measures and therapeutic outcomes
89. Testosterone and the aging male